Since neovascular endothelium cells of various malignancies, including ccRCC, overexpress PSMA, and since ccRCC is considered a highly vascularized tumor, this might be a rationale to employ PET imaging with PSMA-targeting radiopharmaceuticals in tumors with variable [18F]FDG uptake, exploring different biological processes than glucose metabolism. The gene discussed is FOLH1; the disease is nonpapillary renal cell carcinoma.